Improving IL12 immunotherapy in glioblastoma by targeting the long noncoding RNA INCR1
INCR1 silencing affects more immune evasive pathways than PD-L1. Targeting INCR1 may represent a valid approach to improve the efficacy of IL12 therapy in GBM.
Authors
- Josephina A.M.A. Gadet (ORCID: https://orcid.org/0009-0002-0724-385X)
- Shikha Saini (ORCID: https://orcid.org/0000-0003-0557-1649)
- E. Antonio Chiocca
- Marco Mineo (ORCID: https://orcid.org/0000-0001-7608-4579)
- Gordon J. Freeman
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- Journal of Neuro-Oncology
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1007/s11060-025-04978-2
- Citations
- 3
- Primary Topic
- Cancer-related molecular mechanisms research
- Type
- article
- Field-Weighted Citation Impact
- 2.81
Funders
- National Institutes of Health